X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis

By Holly Campbell  |    February 14, 2019
New research by three Milliman actuaries explores the dynamics underlying the relationship between Medicare Part D plan premiums and sharing rebates directly with beneficiaries at the pharmacy...   Read More

PhRMA comments to administration on Medicare Part D proposed rule

By Juliet Johnson  |    January 25, 2019
Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) submitted comments in response to the CMS proposed rule, “Modernizing Part D and Medicare Advantage to Lower Drug Prices and...   Read More

New research shows changes to the six protected classes would harm most vulnerable patients and are unnecessary

By Juliet Johnson  |    January 24, 2019
In Medicare Part D, the six protected classes policy protects vulnerable seniors and low-income beneficiaries with serious and complex health conditions, while also allowing Part D insurance plans...   Read More

Keep the Six Protected Classes, protected

By Juliet Johnson  |    January 22, 2019
Medicare Part D has been successfully providing seniors with comprehensive drug coverage for more than a decade, and one of the cornerstones of the program has been to ensure the sickest and most...   Read More

Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program

By Juliet Johnson  |    September 24, 2018
The changes made to Part D in the Bipartisan Budget Act (BBA) that passed in February threaten the program’s successful competitive structure. While these changes closed the donut hole a year...   Read More

What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?

By Juliet Johnson  |    September 13, 2018
Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines.  These...   Read More

PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs

By Holly Campbell  |    July 16, 2018
Today, PhRMA submitted comprehensive comments to the Department of Health and Human Services (HHS) request for information (RFI), HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs....   Read More

Pass-through rebates do not violate non-interference clause but they do increase savings for seniors

By Jim C. Stansel  |    July 2, 2018
For more than a decade, Medicare Part D has successfully provided seniors with comprehensive prescription drug coverage. Key to its success is a unique, market-based structure of private-sector...   Read More

Medicare Part D cliff ahead

By Juliet Johnson  |    June 21, 2018
Medicare Part D has been providing seniors with access to prescription drug coverage that meets their needs for more than a decade. Today, more than 42 million people are enrolled in Part D and 90...   Read More

Part D cliff looms for seniors, as program stability could be in jeopardy

By Juliet Johnson  |    June 18, 2018
For more than a decade, Medicare Part D has successfully provided seniors comprehensive prescription drug coverage that meets their needs, while its market-based structure has kept overall program...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates